Halozyme (HALO) says the European Commission OK'd an injectable version of J&J's (JNJ) cancer drug, Rybrevant for certain ...

Subcutaneous amivantamab is co-formulated Halozyme's ENHANZE ® drug delivery technology. "We are delighted to announce the European approval of the subcutaneous formulation of amivantamab ...

Halozyme Therapeutics (HALO) announced that Janssen-Cilag International NV, a Johnson & Johnson (JNJ) company, has received European ...

Nevertheless, it is a setback for J&J. The current intravenous formulation of Rybrevant has picked up four FDA approvals in previously untreated and relapsed/refractory EGFR-mutated NSCLC - as a ...

Daiichi Sankyo-partnered anti-HER2 drug Enhertu (trastuzumab deruxtecan) has been cleared by the European Commission for use ...

Subcutaneous Rybrevant is co-formulated with Halozyme's ENHANZE drug delivery technology. The EC approval is supported by positive results from the Phase 3 PALOMA-3 study. The views and opinions ...

Head-to-head comparison data versus osimertinib showed RYBREVANT® (amivantamab ... Inc announced that the U.S. Food and Drug Administration (FDA) has approved CABOMETYX® (cabozantinib) for ...

The commission approved the new formulation in first- and second-line NSCLC settings, in which intravenous Rybrevant is already available.

World Health Day, the Personal Care Products Council (PCPC) launched the #WearSunscreen campaign, a nationwide effort urging the public to protect their skin with sunscreen use every day. Slightly ...